A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy

Khalafallah, Alhossain A; Hyppa, Annemarie; Chuang, Anthony; Hanna, Fayez; Wilson, Emily L.; Kwok, Christine; Yan, Carl; Gray, Zara; Mathew, Ronnie; Falloon, Pete; Dennis, Amanda; Pavlov, Toly; Allen, John C.

doi:10.1053/j.seminhematol.2018.04.006

Cited by 52 publications

(88 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…51.3% in Egypt [6] and 44.5% in Saudi Arabia [31]). Besides, the prevalence of anemia in pregnant population varied across Asia-paci c regions, such as 25.7% in Korea [5], 20%-25% in Australia [32][33][34] and 50% in India [35]. Our ndings were similar to those from developed countries.…”

Section: Discussionsupporting

confidence: 77%

Prevalence of anemia and iron deficiency anemia in Chinese pregnant women (IRON WOMEN): a national cross-sectional survey

Tan

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The current evidence about anemia and iron deficiency anemia (IDA) during pregnancy remains elusive in China. The purpose of this study is to investigate the prevalence of anemia and IDA and their risk factors in Chinese pregnant women.Methods: A nationwide cross-sectional survey of pregnant women was conducted during their antenatal visits. Using a multi-stage sampling method, 24 hospitals from 16 provinces across China were selected. Structured questionnaires were administered to collect information from participants and to extract clinical data from electronic medical records. Mixed-effects logistic regression models were performed to determine the risk factors associated with anemia and IDA.Results: In total, 12,403 pregnant women were enrolled, including 1,018 (8.2%) at the first trimester, 3,487 (28.1%) at the second, and 7,898 (63.7%) at the third. Overall, 19.8% of women were diagnosed with anemia and 13.9% were diagnosed with IDA. The prevalence of anemia and IDA varied among regions and increased by gestational month, peaking at the eighth gestational month (24.0% for anemia and 17.8% for IDA). Pregnant women at advanced stage of gestation, non-local residents, multiple gestations, multiparity, pre-pregnancy underweight, and those experiencing severe nausea or vomiting during pregnancy, were associated with higher risks of anemia and IDA.Conclusions: The prevalence of anemia and IDA during pregnancy are similar to those from developed countries and vary across regions in China.

show abstract

Section: Discussionsupporting

confidence: 77%

Prevalence of anemia and iron deficiency anemia in Chinese pregnant women (IRON WOMEN): a national cross-sectional survey

Tan

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Today, the clinical scenario of iron balance management has deeply changed, thanks to the introduction in the market of new IV iron preparations, like ferric carboxymaltose (FCM) that can be administered in high doses (500-1000 mg) in a single IV administration with acceptable side effects, although in-hospital administration is still requested [23]. This study did not consider in the analysis this "comparator", scarcely available in Italy when the study by Pisani et al was performed; as shown, however, even a single administration of 1 g of carbxymaltose iron should hypothetically cost 74% more than the entire oral cycle with Sucrosomial iron, suggesting that the oral route still remains the most convenient option, at least from an economic point of view; on the other hand, considering the consistent reduction in costs and, mostly, in personnel involvement, the recourse to FCM, widely available on the market, may more easily find a specific indication when oral iron administration cannot be pursued, mostly considering the savings that a correct iron balance allows on costs of ESA treatment and on the days of hospitalization or of work-hour loss that anemia may require.…”

Section: Discussionmentioning

confidence: 99%

Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis

Riccio

Sabbatini²,

Capuano³

et al. 2020

BMC Nephrol

View full text Add to dashboard Cite

Background: Oral iron is recommended as first line treatment of anemia in non-dialysis chronic kidney disease (ND-CKD) patients. Sucrosomial® iron, a new generation oral iron with high absorption and bioavailability and a low incidence of side effects, has shown to be not inferior to intravenous (IV) iron in the replacement of iron deficiency anemia in patients with ND-CKD. Besides the clinical benefit, it is also important to determine the comparative total costs of oral versus IV iron administrations. The aim of this study was to perform a cost-minimization analysis of oral Sucrosomial iron, compared with IV iron gluconate from an Italian societal perspective. Methods: Cost analysis was performed on the 99 patients with ND-CKD and iron-deficiency anemia of the randomized trial by Pisani et al. Human and material resources utilization was recorded during each iron administration. According to study perspective, direct and indirect costs were considered. Costs for each resource unit were taken from official Italian sources. Probabilistic sensitivity analyses were carried out to test the robustness of the results. Results: The base case analysis showed an average cost/cycle per patient of € 111 for oral iron and € 1302 for IV iron. Thus, the potential saving was equal to € 1191 per patient/cycle. The sensitivity analysis showed that the most sensitive driver is the time loss by patient and caregivers for the therapy and related-care, followed by the minutes of nursing care and the number of kilometres travelled to reach the referral centre. Discussion: This study showed that oral Sucrosomial® iron could offer specific advantages in terms of potential savings, and allowed identifying some implications for future research. Such advantages still persist with the new single dose IV iron formulation available in the market, although to a lesser extent.

show abstract

“…S [ 29 ]; IDA: 16% in Belgian, and 3% in Switzerland), but the prevalence remained high in developing nations (for example, anemia: 53.4% in Congo [ 7 ]); IDA: 51.3% in Egypt [ 6 ] and 44.5% in Saudi Arabia [ 30 ]). Besides, the prevalence of anemia in pregnant population varied across Asia-pacific regions, such as 25.7% in Korea [ 5 ], 20–25% in Australia [ 31 – 33 ] and 50% in India [ 34 ]. According to the estimates by WHO, the lowest prevalence of anemia during pregnancy occurred in Western Pacific region (24.3%) and the highest prevalence in South-East Asia region (48.7%) [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Prevalence of anemia and iron deficiency anemia in Chinese pregnant women (IRON WOMEN): a national cross-sectional survey

Tan

et al. 2020

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

Background The current evidence about anemia and iron deficiency anemia (IDA) during pregnancy remains elusive in China. The purpose of this study is to investigate the prevalence of anemia and IDA and their risk factors in Chinese pregnant women. Methods A nationwide cross-sectional survey of pregnant women was conducted during their antenatal visits. Using a multi-stage sampling method, 24 hospitals from 16 provinces across China were selected. Structured questionnaires were administered to collect information from participants and to extract clinical data from electronic medical records. Mixed-effects logistic regression models were performed to determine the risk factors associated with anemia and IDA. Results In total, 12,403 pregnant women were enrolled, including 1018 (8.2%) at the first trimester, 3487 (28.1%) at the second, and 7898 (63.7%) at the third. Overall, 19.8% of women were diagnosed with anemia and 13.9% were diagnosed with IDA. The prevalence of anemia and IDA varied among regions and increased by gestational month, peaking at the eighth gestational month (24.0% for anemia and 17.8% for IDA). Pregnant women at advanced stage of gestation, non-local residents, multiple gestations, multiparity, pre-pregnancy underweight, and those experiencing severe nausea or vomiting during pregnancy, were associated with higher risks of anemia and IDA. Conclusions The prevalence of anemia and IDA during pregnancy are similar to those from developed countries and vary across regions in China.

show abstract

A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy

Cited by 52 publications

References 31 publications

Prevalence of anemia and iron deficiency anemia in Chinese pregnant women (IRON WOMEN): a national cross-sectional survey

Prevalence of anemia and iron deficiency anemia in Chinese pregnant women (IRON WOMEN): a national cross-sectional survey

Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis

Prevalence of anemia and iron deficiency anemia in Chinese pregnant women (IRON WOMEN): a national cross-sectional survey

Contact Info

Product

Resources

About